Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-Maintenance
2022-501515-14-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Sep 2023
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Iberdomide maintenance with Lenalidomide maintenance (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2023; status: authorised.
02
Drugs
iberdomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-501515-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501515-14-00.